ABT-594 [(R)-5-(2-Azetidinylmethoxy)-2-Chloropyridine]: A novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 2, 1998, Pages 777-786

  Donnelly Roberts, Diana L ^a   Puttfarcken, Pamela S ^a   Kuntzweiler, Theresa A ^a   Briggs, Clark A ^a   Anderson, David J ^a   Campbell, Jeffrey E ^a   Piattoni Kaplan, Marietta ^a   Mckenna, David G ^a   Wasicak, James T ^a   Holladay, Mark W ^a   Williams, Michael ^a   Arneric, Stephen P ^b  

^a ABBOTT LABORATORIES   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; ANALGESIC AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; EPIBATIDINE; MORPHINE; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; BINDING AFFINITY; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; HUMAN; HUMAN CELL; ION TRANSPORT; PRIORITY JOURNAL; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ALKALOIDS; ANALGESICS, NON-NARCOTIC; ANIMALS; AZETIDINES; AZOCINES; BICYCLO COMPOUNDS, HETEROCYCLIC; BUNGAROTOXINS; CALCITONIN GENE-RELATED PEPTIDE; CALCIUM; HUMANS; MALE; NICOTINIC AGONISTS; PYRIDINES; QUINOLIZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC; XENOPUS LAEVIS;

EID: 7144229369     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. 3H]ABT-418: A novel cholinergic channel ligand. J Pharmacol Exp Ther 273:1434-1441.
2. Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes M, Cadman ED, Adams P, Garvey DS, Wasicak J and Williams M (1994) (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT-418): A novel cholinergic channel ligand with cognition enhancing and anxiolytic activity: In vitro activity. J Pharmacol Exp Ther 270:310-317.
3. Arneric SP, Sullivan JP and Williams M (1995) Neuronal nicotinic acetylcholine receptors: Novel targets for CNS therapeutics, in Psychopharmacology: 4th Generation of Progress (Bloom FE and Kupfer DJ, eds) pp 94-110, Raven Press, New York.
4. Arneric SP, Campbell JE, Carrol S, Holladay MW, Johnson P, Lin N-H, Marsh KC, Peterson B, Qui Y, Roberts EM, Rodrigues AD, Sullivan JP, Trivedi J and Williams M (1997) ABT-089 [3-(2(S)-[pyrrolidinylmethoxy)-2-methyl-pyridine]: An orally effective cholinergic channel modulator with potential once-a-day dosing and cardiovascular safety. Drug Dev Res 41:31-43.
5. Badio B and Daly JW (1994) Epibatidine, a potent analgesic and nicotinic agonist. Mol Pharmacol 45:563-569.
6. Bannon AW, Gunther KL, Decker MW and Arneric SP (1995) The influence of Bay K 8644 treatment on (±)-epibatidine-induced analgesia. Brain Res 678:244-250.
7. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts D, Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD, Williams M and Arneric SP (1998a) Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 279:77-81.
8. Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJB, Lynch JK, Wasicak JT, Arnold WH, Holladay MW and Arneric SP (1998b) ABT-594 [(R-5-(2-azetidinyl-methoxy)-2-chloropyridine]: A novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors. II. In vivo characterization. J Pharmacol Exp Ther 285:787-794.
9. Briggs CA, McKenna DG and Piattoni-Kaplan M (1995) Human α7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34:583-590.
10. Chen JJ, Barber LA, Dymshitz and Vasko MR (1996) Peptidase inhibitors improve recovery of substance P and calcitonin gene-related peptide release from rat spinal cord slices. Peptides 17:31-37.
11. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
12. Cherny NI (1996) Opioid analgesics: Comparative features and prescribing guidelines. Drugs 51:713-737.
13. Damaj MI, Welch SP and Martin BR (1993) Involvement of calcium and L-type channels in nicotine-induced antinociception. J Pharmacol Exp Ther 266:1330-1338.
14. Decker MW, Bannon AW, Buckley MJ, Kim DJB, Holladay MW, Ryther KB, Lin N-H, Wasicak JR, Williams M and Arneric SP (1998) Antinociceptive effects of the novel cholinergic channel modulator, ABT-594, in mice. Eur J Pharmacol, in press.
15. Dray A, Urban L and Dickenson A (1994) Pharmacology of chronic pain. Trends Pharmacol Sci 15:190-197.
16. Flores CM, Rogers SW, Pabreza LA, Wolfe B and Kellar KJ (1992) A subtype of nicotinic cholinergic receptor is composed of α4 and β2 subunits and is upregulated by chronic nicotine treatment. Mol Pharmacol 41:31-37.
17. Flores CM, DeCamp RM, Kilo S, Rogers SW and Hargreaves KM (1996) Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of α3β4, a novel subtype in the mammalian nervous system. J Neurosci 16:7892-7901.
18. Forsayeth JR and Kobrin E (1997) Formation of oligomers containing the β3 and β4 subunits of the rat nicotinic receptor. J Neurosci 17:1531-1538.
19. Gamse R, Molnar A and Lembeck F (1979) Substance P release from spinal cord slices by capsaicin. Life Sci 25:629-636.
20. Garry MG, Durnett Richardson J and Hargreaves KM (1994) Sodium nitroprusside evokes the release of immunoreactive calcitonin-gene-related peptide and substance P from dorsal horn slices via nitric oxide-dependent and nitric oxide-independent mechanisms. J Neurosci 14:4329-4337.
21. Gerzanich V, Kuryatov A, Anand R and Lindstrom J (1997) Orphan α6 nicotinic AChR subunit can form a functional heteromeric acetylcholine receptor. Mol Pharmacol 51:320-327.
22. Gopalakrishnan M, Buisson B, Tuoma E, Giordano T, Campbell JE, Hu IC, Bertrand D, Donnelly-Roberts D, Arneric SP and Sullivan JP (1995) Pharmacological characterization of the human α7 neuronal nicotinic acetylcholine receptor subtype stably expressed in a mammalian cell line. Eur J Pharmacol 290:237-246.
23. Gopalakrishnan M, Monteggia LM, Anderson DJ, Piattoni-Kaplan M, Donnelly-Roberts D, Arneric SP and Sullivan JP (1996) Stable expression, pharmacologic properties and regulation of human nicotinic acetylcholine α4β2 receptor. J Pharmacol Exp Ther 276:289-297.
24. Hancock AA, Buckner SA, Giardina WJ, Brune ME, Lee JY, Morse PA, Oheim KW, Stanistic DS, Warner RB, Kerkman DJ and DeBernardis JF (1995) Preclinical pharmacological actions of (±)-(1′R*,3R*)-#-phenyl-1-[(1′, 2′3′4′-terahydro-5′,6′-methylene-dioxy-1′- napthalenyl) methyl] pyrrolidine methanesulfonate (ABT-200), a potential antidepressant agent that antagonizes alpha-2 adrenergic receptors and inhibits the neuronal uptake of norepinephrine. J Pharmacol Exp Ther 272:1160-1169.
25. Holladay MW, Dart MJ and Lynch JK (1997) Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem 40:4169-4194.
26. Holladay MW, Wasicak JT, Lin N-H, He Y, Ryther KB, Bannon AW, Buckley MJ, Kim DJB, Decker MW, Anderson DJ, Campbell JE, Kuntweiler TA, Donnelly-Roberts DL, Piattoni-Kaplan M, Briggs CA, Williams M and Arneric SP (1998) Identification and structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J Med Chem 41:407-412.
27. Jinno S, Hua X-Y and Yaksh TL (1994) Nicotine and acetylcholine induce release of calcitonin gene-related peptide from rat trachea. J Physiol 76:1651-1656.
28. Khan IM, Yaksh TL and Taylor P (1994) Ligand specificity of nicotinic acetylcholine receptors in rat spinal cord: Studies with nicotine and cytisine. J Pharmacol Exp Ther 270:159-166.
29. Khan IM, Yaksh TL and Taylor P (1997) Epibatidine binding sites and activity in the spinal cord. Brain Res 753:269-282.
30. Lukaa RJ (1993) Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal cell line. J Pharmacol Exp Ther 265:294-302.
31. Minta A, Kao R and Tsien J (1989) Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. J Biol Chem 264:8171-8180.
32. Neumann S, Doubell TP, Leslie T and Woolf CJ (1996) Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature 384:360-364.
33. Puttfarcken PS, Manelli AM, Arneric SP and Donnelly-Roberts DL 1997) Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: Studies with F11 cells. J Neurochem 69:930-938
34. Qian C, Li T, Shen TY, Libertine-Garahan L, Eckman J, Biftu T, Ip S (1993) Epibatidine is a nicotinic analgesic. Eur J Pharmacol 250:R13-R14.
35. Rao TS, Correa LD, Reid RT and Lloyd GK (1996) Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (nAChR) ligands in the rat tail flick assay. Neuropharmacology 35:393-405.
36. Role LW and Berg DK (19961 Nicotinic receptors in the development and modulation of CNS synapses. Neuron 16:1077-1085.
37. Sargent PB(1993) The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 16:403-443.
38. Smart D and Lambert DG (1996) The stimulatory effects of opioids and their possible role in the development of tolerance. Trends Pharmacol Sci 17:264-269.
39. Spande TF, Garraffo HM, Edwards MW, Yeh HJC, Pannell L, Daly JW (1992) Epibatidine: A novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Ecuadorian poison frog. J Am Chem Soc 114:3475-3478.
40. Sullivan JP and Bannon A (1996) Epibatidine: Pharmacological properties of a novel nicotinic acetylcholine receptor agonist and analgesic agent. CNS Drug Rev 2:21 -39.
41. Sullivan JP, Decker MW, Brioni JD, Roberts-Donnelly D, Anderson DJ, Bannon A, Gopalakrishnan M, Piattoni-Kaplan M, Adams P, Buckley MJ, Kang CH, Williams M, Arneric SP (1994) Pharmacological properties of (±)-epibatidine: A potent nicotinic acetylcholine receptor ligand. J Pharmacol Exp Ther 271:624-631.
42. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Piattoni-Kaplan M, Campbell JE, McKenna DG, Molinari E, Hettinger, A-M, Garvey DS, Wasicak JT, Holladay MW, Williams M and Arneric SP (1996) A-85380 [3-(2(S)-azetidinylmethoxy)pyridine]: in vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand. Neuropharmacol 35:725-734.
43. Sullivan JP, Donnelly-Roberts D, Briggs CA, Anderson DJ, Gopalakrishnan M, Xue IC, Piattoni-Kaplan M, Molinari E, Campbell JE, McKenna DG, Gunn DE, Lin, N-H, Ryther KBHEY, Holladay MW, Wonnacott S, Williams M and Arneric SP (1997) ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: 1. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther 283:235-246.
44. Wilson PT, Hawrot E and Lentz TL (1988) Distribution of α-bungarotoxin binding sites over residues 173-204 of the α-subunit of the acetylcholine receptor. Mol Pharmacol 34:643-650.
45. Zoli M, Le Novere N, Hill JA and Changeux J-P (1995) Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. J Neurosci 15:1912-1939.